Durata Therapeutics Stock Price, News & Analysis (NASDAQ:DRTX)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Durata Therapeutics (NASDAQ:DRTX)

Durata Therapeutics logoDurata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.

Receive DRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Durata Therapeutics (NASDAQ:DRTX) Frequently Asked Questions

What is Durata Therapeutics' stock symbol?

Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."

Who are some of Durata Therapeutics' key competitors?

How do I buy Durata Therapeutics stock?

Shares of Durata Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Durata Therapeutics?

Durata Therapeutics' mailing address is 200 S Wacker Dr Ste 2550, CHICAGO, IL 60606-5811, United States. The biotechnology company can be reached via phone at +1-312-2197000.

MarketBeat Community Rating for Durata Therapeutics (DRTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about Durata Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Durata Therapeutics (NASDAQ:DRTX) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Durata Therapeutics (NASDAQ:DRTX) Earnings History and Estimates Chart

Earnings by Quarter for Durata Therapeutics (NASDAQ:DRTX)

Durata Therapeutics (NASDAQ DRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2014Q2($0.73)($0.61)ViewN/AView Earnings Details
5/8/2014Q114($0.61)($0.65)ViewN/AView Earnings Details
3/14/2014Q413($0.76)($0.59)ViewN/AView Earnings Details
11/6/2013Q3 2013($0.60)($0.45)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.52)($0.75)ViewN/AView Earnings Details
5/9/20131Q13($0.66)($0.86)ViewN/AView Earnings Details
11/9/2012Q312($1.00)($1.47)ViewN/AView Earnings Details
9/4/2012Q2 2012($1.08)($256.56)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Durata Therapeutics (NASDAQ:DRTX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com


Dividend History for Durata Therapeutics (NASDAQ:DRTX)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Durata Therapeutics (NASDAQ DRTX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Durata Therapeutics (NASDAQ:DRTX)

Durata Therapeutics (NASDAQ DRTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2014John Patrick Shannon JrInsiderBuy3,000$13.72$41,160.00View SEC Filing  
6/12/2014Paul R EdickCEOBuy3,000$15.23$45,690.00View SEC Filing  
5/12/2014Schutter Richard DeDirectorBuy15,000$15.57$233,550.0015,000View SEC Filing  
3/21/2014Aisling Capital Iii Lpmajor shareholderSell100,649$15.74$1,584,215.26View SEC Filing  
12/3/2013Lisa GilesDirectorBuy1,000$10.95$10,950.001,000View SEC Filing  
5/20/2013Paul R EdickCEOBuy3,000$7.09$21,270.00View SEC Filing  
8/14/2012Paul R EdickCEOBuy5,000$8.65$43,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Durata Therapeutics (NASDAQ DRTX) News Headlines

No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Durata Therapeutics (NASDAQ:DRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Durata Therapeutics (NASDAQ:DRTX) Income Statement, Balance Sheet and Cash Flow Statement


Durata Therapeutics (NASDAQ DRTX) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.